Combining PD-1 blockade with 90Y-NM600 led to an unexpected decrease in anti-tumor efficacy that was found to be due to increased activity of PD-1-expressing CD4+ Treg that persisted in tumors despite TRT treatment. Here, CD4 is linked to neoplasm.